Using an experimental medicine approach incorporating currently accepted gold‐standard noninvasive metabolic assessments in patients with NAFLD, we have assessed the impact of SGLT2 inhibition using dapagliflozin on the tissue‐specific insulin‐regulated processes that drive the accumulation of TAG within the liver. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.